New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2013
08:09 EDTMACKMerrimack to present Phase 1 data on potential breast cancer treatment
Merrimack Pharmaceuticals announced that Phase 1 data evaluating safety of the novel agent MM-302 in patients with advanced HER2-positive breast cancer will be presented at the 2013 San Antonio Breast Cancer Symposium, December 10-14, 2013 in San Antonio, Texas. The Phase 1 trial for MM-302 enrolled patients with advanced HER2-positive breast cancer who have progressed or recurred on standard therapy. Data to be presented will include safety results for all treated patients in the trial, as well as preliminary activity in patients treated with therapeutically relevant dose levels of MM-302 alone and in combination with trastuzumab. In addition, results will be presented from a research collaboration with the laboratory of Peter Sorger, Ph.D., from Harvard Medical School. In this collaboration, statistical models were used to generate preclinical response biomarker hypotheses for targeted inhibitors.
News For MACK From The Last 14 Days
Check below for free stories on MACK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for MACK

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use